Adria's Mycobutin (rifabutin)
Under its approved Treatment IND application, the company will not charge AIDS patients for the drug, which delays or prevents Mycobacterium avium complex ("The Pink Sheet" March 9, T&G-13). Distribution of rifabutin is being handled by PACT, a clinical consulting firm. Through an "800" telephone number for physicians, PACT will enroll eligible patients into the program and deliver a three-month supply for physicians to provide to patients. Adria said it has rifabutin ready for 5,000 patients. The company submitted a rolling NDA for the drug on Jan. 17.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth